Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

BOVen Regimen Is Safe and Effective in First-Line TP53-Mutated MCL

March 11th 2025

BOVen met the primary end point of 2-year PFS in a phase 2 study, displaying high response rates in treatment-naive TP53-mutated MCL.

Acalabrutinib Plus Bendamustine and Rituximab Displays Long-Term Activity in Frontline and R/R MCL

March 11th 2025

Acalabrutinib plus BR showed OS and PFS efficacy with a tolerable safety profile with long-term follow-up in first-line and R/R MCL.

Dato-DXd Plus Durvalumab ± Carboplatin Delivers Antitumor Activity in Advanced NSCLC

March 10th 2025

Frontline treatment with datopotamab deruxtecan plus durvalumab with/without carboplatin proved active in advanced NSCLC without actionable alterations.

Novel Index Identifies Social Vulnerability Barriers to Cancer Clinical Trial Enrollment

March 10th 2025

Lower odds of enrollment in cancer clinical trials could be associated with education, transportation, and neighborhood resources.

Zongertinib Displays Early Activity and Tolerability in HER2-Mutated Solid Tumors

March 10th 2025

Zongertinib showed responses across HER2-mutated tumor types, including in lung cancer, with a tolerable safety profile.

Real-World Findings Support the Safety of Frontline Ribociclib Plus ET for HR+/HER2-Negative Metastatic Breast Cancer

March 7th 2025

The real-world use of ribociclib plus ET is in line with recommended dosing and the regimen’s use has been increasing in mBC, according to EHR and KRD data.

Perioperative Durvalumab Plus Chemo Meets EFS End Point in Resectable Gastric/GEJ Cancer

March 7th 2025

Perioperative durvalumab plus FLOT improved event-free survival in resectable gastric or gastroesophageal junction cancer.

Nivolumab Plus Ipilimumab Receives EC Approval for First-Line Unresectable HCC

March 7th 2025

Nivolumab plus ipilimumab was approved by the European Commission for first-line, unresectable or advanced HCC.

Sacituzumab Govitecan Produces Comparable Real-World OS Results, Low Rates of Neutropenia in Metastatic TNBC

March 7th 2025

Sacituzumab govitecan was active with low rates of neutropenia—especially in patients receiving G-CSF—in real-world metastatic TNBC.

Ensartinib Looks to Find a Place in ALK+ NSCLC Paradigm Alongside Approved TKIs

March 5th 2025

Alberto Chiappori, MD, details how to select between ensartinib and approved ALK TKIs for NSCLC, as well as considerations with ensartinib’s FDA approval.

ARX788 Displays Activity in HER2+ Advanced Breast Cancer

March 5th 2025

ARX788 was safe and effective in HER2+ advanced breast cancer after disease progression on 1 line of a trastuzumab-based regimen.

Nivolumab/Ipilimumab Combination Represents Potential Standard-of-Care Shift in MSI-H/dMMR mCRC

March 5th 2025

Thierry André, MD, discusses findings from the phase 3 CheckMate 8HW trial of nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

Combination Regimens Expand CLL Treatment Paradigm

March 4th 2025

During an OncLive Peer Exchange at the 2024 ASH Meeting, expert investigators in hematology discussed findings from several clinical trial updates in CLL.

Quizartinib Plus Chemotherapy Is Set to Be Evaluated in FLT3-ITD-Negative AML in Phase 3 Trial

March 3rd 2025

Quizartinib with 7+3 chemotherapy was safe and effective in patients with FLT3-ITD–negative AML, leading to the initiation of the phase 3 QuANTUM-Wild trial.

Beyond Serum Tryptase: Exploring Additional Testing Approaches for Indolent Systemic Mastocytosis

February 28th 2025

Tracy I. George, MD, discusses testing considerations in indolent systemic mastocytosis, including the role of serum tryptase and KIT D816V testing.

The Rapid Evolution of Multiple Myeloma Treatment in Recent Years

February 27th 2025

Multiple myeloma experts offer their perspectives on the evolution of the treatment landscape over the past 10 years and look towards the future of care.

Zamto-Cel Represents Potential New CAR T Approach in R/R DLBCL

February 27th 2025

Nirav N. Shah, MD, discusses findings from the phase 2 DALY II USA of zamto-cel in relapsed/refractory DLBCL.

Drawing Professional Inspiration From Personal Experience

February 27th 2025

Bradley Muller, MD, discusses how his experience as a patient with cancer led to him working to improve outcomes for the next generation of patients.

Divesiran Is Tolerable and Shows Positive Early Signals in Polycythemia Vera

February 26th 2025

The siRNA divesiran was well-tolerated and reduced the number of phlebotomies that were required in patients with polycythemia vera.

First-Line Camizestrant Plus CDK4/6 Inhibition Boosts PFS in ESR1+, HR+/HER2-Negative Advanced Breast Cancer

February 26th 2025

Camizestrant plus a CDK4/6 inhibitor was safe and effective in frontline ESR1-mutated HR-positive/HER2-negative advanced breast cancer.